Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Novo Nordisk A/S
Develops, manufactures, markets and distributes pharmaceutical products

Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products.

It operates through the Diabetes and Obesity Care, and Biopharmaceuticals segments.

The Diabetes and Obesity Care segment covers insulins, glucagon-like-peptide 1, other protein-related products, oral anti-diabetic drugs and obesity.

The Biopharmaceuticals segment involves in the research, development, manufacture, and distribution of products within the areas of haemophilia, growth hormone, hormone replacement, inflammation, and therapy areas.

The company was founded by August Krogh, Marie Krogh, Hans Christian Hagedorn, August Kongsted, Harald Pedersen, and Thorvald Pedersen in 1923 is headquartered in Bagsvćrd, Denmark.

Number of employees : 41 971 persons.
Sales per Businesses
20152016Delta
DKK (in Million)%DKK (in Million)%
Diabetes & Obesity Care85,59079.3%88,94979.6% +3.92%
Biopharmaceuticals22,33720.7%22,83120.4% +2.21%
Sales per Regions
20152016Delta
DKK (in Million)%DKK (in Million)%
North America56,85752.7%---
Europe20,79819.3%20,68218.5% -0.56%
International14,96613.9%14,05012.6% -6.12%
Region China9,8719.1%10,4589.4% +5.95%
Japan & Korea5,4355%---
United States--57,19451.2%-
Pacific--9,3968.4%-
Managers
NameAgeSinceTitle
Lars Fruergaard Jřrgensen, MBA511991President & Chief Executive Officer
Göran Ando682005Chairman
Jesper Brandgaard, MBA541999Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen, PhD571991Chief Science Officer & Executive Vice President
Mads Krogsgaard--Chief Science Officer
Anne Marie Handrup Kverneland611981Director
Stig Strřbćk531992Director
Elizabeth Anne Hewitt612012Independent Director
Sřren Thuesen Pedersen, MBA531994Director
Jeppe Fonager Christiansen582013Vice Chairman
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 1,962,564,000 1,753,082,748 89.3% 45,667,252 2.3% 70.1%
Share B 10 537,436,000 0 0.0% 0 0.0%
Shareholders
NameEquities%
Novo Nordisk Fonden 163,814,000 8.35%
Norges Bank Investment Management 42,958,316 2.19%
The Vanguard Group, Inc. 42,067,392 2.14%
Capital Research & Management Co. (World Investors) 30,113,915 1.53%
Novo Nordisk A/S 29,192,349 1.49%
Alecta Pension Insurance Mutual 28,698,000 1.46%
Northern Cross LLC 19,357,465 0.99%
BlackRock Fund Advisors 17,801,100 0.91%
Jupiter Asset Management Ltd. 16,207,415 0.83%
Flossbach von Storch AG 15,316,427 0.78%
Holdings
NameEquities%Valuation
Novo Nordisk A/S (NOVO B) 29,192,3491.49%1,248,516,189 USD
Nnit A/S (NNIT) 6,375,00025.5%194,121,236 USD
Innate Pharma (IPH) 8,908,45615.5%111,054,683 USD
Pieris Pharmaceuticals Inc (PIRS) 0
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
NOVO NORDISK A/S7.30%84 148
JOHNSON & JOHNSON17.45%364 503
ROCHE HOLDING LTD.4.90%221 492
NOVARTIS8.37%220 936
PFIZER3.08%199 378
MERCK AND COMPANY6.39%171 303
SANOFI6.01%119 827
BAYER11.97%107 019
GLAXOSMITHKLINE3.39%103 206
ELI LILLY AND COMPANY15.11%93 410
BRISTOL-MYERS SQUIBB COMPANY-4.77%91 680
ABBOTT LABORATORIES32.36%88 221
ASTRAZENECA16.10%84 581
ALLERGAN PLC19.50%84 293
SHIRE-11.26%48 950
TAKEDA PHARMACEUTICAL CO LTD17.52%40 859
TEVA PHARMACEUTICAL INDUSTRIES LIMITED-16.27%32 966
ASTELLAS PHARMA INC-17.59%25 306
CHUGAI PHARMACEUTICAL CO LTD39.05%23 709
MYLAN NV2.67%20 994
JIANGSU HENGRUI MEDICINE CO., LTD9.69%20 778
Connections : Novo Nordisk A/S
Archimedes Pharma UK Ltd.
Hofor Forsyning A/S
Bio*One Capital Pte Ltd.
Maj Invest Holding A/S
EUSA Pharma (Europe) Ltd.
Novo Nordisk Holding Ltd.
RAND Health
EUSA Pharma (UK) Ltd.
The International Centre for Missing & Exploited Children
Fondsmćglerselskabet Maj Invest A/S (Broker)
Essex Woodlands Health Ventures UK Ltd.
Steno Diabetes Center A/S
Harno Invest A/S
Novo Nordisk Fonden
Novo Nordisk China Pharmaceuticals Co. Ltd.
NNE Pharmaplan A/S
University of Copenhagen
HOFOR Forsyning Holding A/S
SWMF Life Science Venture Fund LP
Silverwood Property Ltd.
Novo Nordisk Region Japan & Korea A/S
Novo Nordisk Region Europe A/S
Novo Nordisk Region International Operations A/S
Hofor Forsyning Komplementar A/S
Novo Nordisk Gsc Holding A/S
Novo Nordisk Pharmaceuticals A/S
Fondsmćglerselskabet Maj Invest A/S
Novo Nordisk Invest 2 A/S
Haldor Topsoe A/S
Novo Nordisk Region China A/S
Novo Nordisk Region North America Ii A/S
SC Triton Industry SRL
Company contact information
Novo Nordisk A/S
Novo Allé
Bagsvćrd, Capital Region 2880

Phone : +45.44.44.88.88
Web : www.novonordisk.com
© 2017 People , Fundamentals and Ownership